Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation

In current work, we prepared a series of nine 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones using a two-step pathway. Compounds 1-9 were tested in vitro using a set of three proteins recognized as important targets in diabetes and related diseases: PPAR alpha, PPAR gamma, and GLUT-4. Compounds 1-3, 5, and 7 showed significant increases in the mRNA expression of PPAR gamma and GLUT-4, whereas compounds 1-3 did it over PPAR alpha. Compounds 1-3 were identified as a dual PPAR alpha/gamma modulators and were selected for evaluating the in vivo antidiabetic action at 100 mg/kg dose, being orally actives and decreasing blood glucose concentration in a hyperglycemic mice model, as well as reducing the triacylglycerides levels in normolipidemic rats. Docking and molecular dynamics studies were conducted to clarify the dual effect and binding mode of compounds 1-3 on both PPARs. Compounds 2 and 3 exhibited robust in vitro and in vivo efficacy and could be considered dual PPAR modulators with antidiabetic and antidyslipidemic effects.

Automated summary

In this study, a series of nine compounds were synthesized and tested for their effects on proteins related to diabetes. Compounds 1-3 were identified as dual PPARα/γ modulators and showed potential therapeutic effects for both diabetes and dyslipidemia.